Stifel Maintains DocGo(DCGO.US) With Buy Rating, Cuts Target Price to $5.5
Northland Securities Maintains DocGo(DCGO.US) With Buy Rating, Cuts Target Price to $6
DocGo Is Maintained at Buy by Stifel
Stifel Maintains Buy on DocGo, Lowers Price Target to $5.5
DocGo Is Maintained at Buy by Needham
DocGo Analyst Ratings
BTIG Maintains DocGo(DCGO.US) With Buy Rating, Maintains Target Price $8
CCORF Maintains DocGo(DCGO.US) With Buy Rating, Maintains Target Price $5
Needham Maintains DocGo(DCGO.US) With Buy Rating, Cuts Target Price to $4
Optimistic Buy Rating for DocGo Amid Strategic Transition and Growth Potential
BTIG Maintains DocGo(DCGO.US) With Buy Rating, Maintains Target Price $8
BTIG Maintains DocGo(DCGO.US) With Buy Rating, Raises Target Price to $8
DocGo Analyst Ratings
Needham Maintains DocGo(DCGO.US) With Buy Rating, Maintains Target Price $7
Northland Securities Maintains DocGo(DCGO.US) With Buy Rating, Maintains Target Price $8
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), DocGo (DCGO) and Alkermes (ALKS)
Northland Securities Maintains DocGo(DCGO.US) With Buy Rating, Maintains Target Price $8
Northland Securities Maintains DocGo(DCGO.US) With Buy Rating, Maintains Target Price $8
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and DocGo (DCGO)
Deutsche Bank Maintains DocGo(DCGO.US) With Buy Rating, Maintains Target Price $5